Abstract |
Rearrangement of anaplastic lymphoma kinase (ALK) gene is detected in approximately 5% of non-small cell lung cancer (NSCLC) patients. Tyrosine kinase inhibitors targeting ALK have significantly improved the prognosis of these patients. However, most patients experienced disease progression within a few years due to acquired resistance. Brigatinib is a second-generation ALK inhibitor effective in presence of several ALK mutations with demonstrated activity against central nervous system metastases. Currently, brigatinib is approved to treat ALK-positive metastatic NSCLC patients not previously treated with ALK inhibitors and patients who have progressed on or are intolerant to crizotinib. In this review, we provide a summary of results from clinical trials involving brigatinib, and we discuss its possible role in the management of ALK-positive NSCLC in the following years.
|
Authors | Erika Rijavec, Federica Biello, Alice Indini, Francesco Grossi, Carlo Genova |
Journal | Clinical pharmacology : advances and applications
(Clin Pharmacol)
Vol. 14
Pg. 1-9
( 2022)
ISSN: 1179-1438 [Print] New Zealand |
PMID | 35082536
(Publication Type: Journal Article, Review)
|
Copyright | © 2022 Rijavec et al. |